Louise Wang Zhiying Humphrey

Array ( [id] => 14897561 [patent_doc_number] => 20190292546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => TLR3 AGONIST FOR USE FOR INDUCING APOPTOSIS IN SENESCENT CANCER CELLS [patent_app_type] => utility [patent_app_number] => 16/348775 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16532113 [patent_doc_number] => 10874688 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Double-stranded nucleic acid molecule and use thereof [patent_app_type] => utility [patent_app_number] => 16/345296 [patent_app_country] => US [patent_app_date] => 2017-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 12630 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696962 [patent_doc_number] => 10947545 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Aptamers for use in inhibition and/or suppression of TLR9 activation [patent_app_type] => utility [patent_app_number] => 16/349396 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10620 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14808419 [patent_doc_number] => 20190270819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => INTEGRIN ALPHA 9 BLOCKADE SUPPRESSES LYMPHATIC VALVE FORMATION AND PROMOTES TRANSPLANT SURVIVAL [patent_app_type] => utility [patent_app_number] => 16/344741 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14948865 [patent_doc_number] => 10435692 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 15/793441 [patent_app_country] => US [patent_app_date] => 2017-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 77 [patent_figures_cnt] => 77 [patent_no_of_words] => 73728 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15793441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975766 [patent_doc_number] => 11492616 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Method for modifying amino acid attenuator and use of same in production [patent_app_type] => utility [patent_app_number] => 16/345669 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 62021 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 484 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915793 [patent_doc_number] => 10655127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => RNA amidates and thioamidates for RNAi [patent_app_type] => utility [patent_app_number] => 15/786974 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 35 [patent_no_of_words] => 11607 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15786974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743841 [patent_doc_number] => 20190255094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => GUIDE RNA COMPLEMENTARY TO KRAS GENE, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/341585 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12159183 [patent_doc_number] => 20180030449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'REPLICATION CAPABLE rAAV VECTORS ENCODING INHIBITORY siRNA AND METHODS OF THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/728447 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 7806 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14296959 [patent_doc_number] => 10288602 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Screening method, a kit, a method of treatment and a compound for use in a method of treatement [patent_app_type] => utility [patent_app_number] => 15/727851 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 21 [patent_no_of_words] => 14177 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15727851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151821 [patent_doc_number] => 20180023085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 15/726805 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 15168 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12240161 [patent_doc_number] => 20180073024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'CHIMERIC DOUBLE-STRANDED NUCLEIC ACID' [patent_app_type] => utility [patent_app_number] => 15/725845 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 28389 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15725845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219235 [patent_doc_number] => 20180057594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/720696 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 41728 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15720696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17937101 [patent_doc_number] => 11471533 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Compound usable as cationic lipid [patent_app_type] => utility [patent_app_number] => 16/336668 [patent_app_country] => US [patent_app_date] => 2017-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 16807 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16336668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17286256 [patent_doc_number] => 11202794 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor [patent_app_type] => utility [patent_app_number] => 16/334725 [patent_app_country] => US [patent_app_date] => 2017-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 31111 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17286255 [patent_doc_number] => 11202793 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => High purity RNA compositions and methods for preparation thereof [patent_app_type] => utility [patent_app_number] => 16/333330 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 52 [patent_no_of_words] => 38229 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12791650 [patent_doc_number] => 20180155719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/704749 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715549 [patent_doc_number] => 20190248838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/333219 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15055405 [patent_doc_number] => 10457994 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => 4-miRNA signature for predicting clear cell renal cell carcinoma metastasis and prognosis [patent_app_type] => utility [patent_app_number] => 15/702681 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 8067 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15702681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15239441 [patent_doc_number] => 20190374506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/739938 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739938 [rel_patent_id] =>[rel_patent_doc_number] =>)